AIT gains FDA nod for imaging/biopsy system:
This article was originally published in Clinica
Advanced Imaging Technologies (AIT) has gained US FDA 510(k) clearance for a breast biopsy capability on its Avera breast imaging system. The new indication will allow physicians to perform immediate biopsies on suspicious breast masses during an Avera imaging session, as the patient does not have to move from their position, says the Preston, Washington firm. Additionally, the biopsy procedure can be performed sooner; sometimes the period between mass detection and biopsy can be several days, says AIT.
You may also be interested in...
The US Food and Drug Administration posted two device-related closeout letters in November.
Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.
As arguments rage over whether the UK regulator has rushed its assessment of the Pfizer/BioNTech vaccine, the European Medicines Agency explains why its conditional marketing authorization approach is taking a little longer.